Anticoagulation: The present and future

Clinical and Applied Thrombosis/Hemostasis

Volumn 7, Issue 3, 2001, Pages 195-204

  Van Aken, Hugo ^a   Bode, Christoph ^b   Darius, Harald ^c   Diehm, Curt ^d   Encke, Albrecht ^e   Gulba, Dietrich C ^f   Haas, Sylvia ^g   Hacke, Werner ^h   Puhl, Wolfhart ⁱ   Quante, Markus ^j   Riess, Hanno ^k   Scharf, Rüdiger ^l   Schellong, Sebastian ^m   Schrör, Karsten ^l   Schulte, Karl Ludwig ⁿ   Tebbe, Ulrich ^o  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d Klinikum Karlsbad   (Germany)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^f Krankenhaus Duren gem GmbH   (Germany)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^h UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

ⁱ Abteilung Innere Medizin II   (Germany)

^j Abteilung für Orthopädie   (Germany)

^k CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^l HEINRICH HEINE UNIVERSITY   (Germany)

^m UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

ⁿ MARTIN LUTHER KRANKENHAUS   (Germany)

^o KLINIKUM LIPPE DETMOLD   (Germany)

more..

Author keywords

Anticoagulation; Coumarin; Direct thrombin inhibitor (dti); Heparin; Thrombin; Ximelagatran

Indexed keywords

ACETYL DEXTRO PHENYLALANYLPROLYLBOROARGININE; ANTICOAGULANT AGENT; BMS 186282; COUMARIN ANTICOAGULANT; DEXTRO PHENYLALANYLPROLYLARGINYL CHLOROMETHYL KETONE; EFEGATRAN; HEPARIN DERIVATIVE; HIRUDIN; INOGATRAN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; THROMBIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; WARFARIN;

ANTICOAGULATION; BLEEDING; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; LUNG EMBOLISM; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; THROMBOSIS;

ADMINISTRATION, ORAL; AMINO ACID CHLOROMETHYL KETONES; ANTICOAGULANTS; AZETIDINES; BENZYLAMINES; BINDING SITES; BIOLOGICAL AVAILABILITY; BLOOD COAGULATION; CEREBROVASCULAR ACCIDENT; COMORBIDITY; COUMARINS; DRUG DESIGN; EMBOLISM; FEMALE; FORECASTING; GLYCINE; GUANIDINES; HEART DISEASES; HEMORRHAGE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HIRUDIN THERAPY; HUMANS; NEOPLASMS; PIPECOLIC ACIDS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PRODRUGS; SAFETY; SERINE; THROMBIN; THROMBOPHILIA; THROMBOSIS;

EID: 0034967038     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960100700303     Document Type: Review

References (70)

1. Blood coagulation
2. Thrombin hypothesis of thrombin generation and vascular lesion formation
3. New antithrombotic agents
4. Molecules in focus. Thrombin
5. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis
6. Biverkningsnytt. Rekordantal rapporter 1992
7. Risk factors for intracranial hemorrhage in outpatients taking warfarin
8. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety
9. The emerging role of low-molecular-weight heparin in cardiovascular medicine
10. Heparin and platelets
11. Unfractionated versus low-molecular-weight heparin in the treatment of venous thromboembolism
12. Reactivation of unstable angina after the discontinuation of heparin
13. New thrombin inhibitors in cardiovascular disease
14. Cardiovascular chemotherapy: Anticoagulants
15. New Antithrombotic agents
16. Site-directed mutagenesis to investigate the basis for the specificity of hirudin
17. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement
18. Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: A multicenter prospective dose-ranging randomized trial
19. Recombinant hirudin for anticoagulation during extracorporeal circulation: Massive postoperative bleeding due to intraoperative hemofiltration
20. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries
21. FDA panel votes against approval for bivalirudin
22. Clinical outcomes of bivalirudin for ischemic heart disease
23. Direct thrombin inhibitors
24. Synthetic inhibitors of thrombin and factor Xa: From bench to bedside
25. Progress towards the discovery of orally active thrombin inhibitors
26. Challenges in the development of orally bioavailable thrombin active site inhibitors
27. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis
28. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors
29. Prevention of deep-vein thrombosis after total hip replacement: Direct thrombin inhibition with recombinant hirudin, CGP 39393
30. New antithrombotic agents
31. Anticoagulation: The old and the new
32. Antithrombin agents: The new class of anticoagulant and antithrombotic drugs
33. In vitro effects of inogatran, a selective low molecular weight thrombin inhibitor
34. Melagatran
35. Novastan® (brand of argatroban): A small-molecule, direct thrombin inhibitor
36. Drug forecast: Focus on argatroban
37. Crystallographic determination of the structures of human alphathrombin complexed with BMS-186282 and BMS-189090
38. Intestinal absorption properties and pharmacodynamic effects of the oral, direct thrombin inhibitor H 376/95 and its active form melagatran
39. Effects of melagatran, a new low-molecular weight thrombin inhibitor, on thrombin and fibrinolytic enzymes
40. H 376/95, an oral, direct thrombin inhibitor, and melagatran, its active form, delay and inhibit thrombin generation
41. Inhibition of thrombin generation by the oral direct thrombin inhibitor H 376/95 in shed blood from healthy male subjects
42. Melagatran, hirudin and heparin as adjuncts to tissue-type plasminogen activator in a canine model of coronary artery thrombolysis
43. Antithrombotic effect of two low molecular weight thrombin inhibitors and a low-molecular weight heparin in a caval vein thrombosis model in the rat
44. Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery
45. The antithrombotic effects of the oral, direct thrombin inhibitor H 376/95 and other anticoagulants tested in a deep venous thrombosis treatment conscious rat model
46. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat
47. Effects of melagatran, a novel direct thrombin inhibitor, in healthy volunteers following intravenous, subcutaneous and oral administration
48. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT
49. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: Intestinal absorption properties, biochemical and pharmacodynamic effects
50. Pharmacodynamic properties of H 376/95, a prodrug of the direct thrombin inhibitor melagatran, intended for oral use
51. Single and repeated oral dosing of H 376/95, a prodrug of the direct thrombin inhibitor melagatran, to young healthy male subjects
52. METHRO I: Dose ranging study H 376/95, a novel, oral, direct thrombin inhibitor, and its subcutaneous formulation, melagatran, for prophylaxis of venous thromboembolism after total hip and total knee replacement
53. Subcutaneous and oral direct thrombin inhibitors for prophylaxis of deep venous thrombosis and pulmonary embolism after total hip and knee replacement
54. METHRO II: Dose-response study of the novel oral, direct thrombin inhibitor, H 376/95, and its subcutaneous formulation melagatran, compared with dalteparin as thromboembolic prophylaxis after total hip replacement or total knee replacement
55. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden
56. The duration of oral anticoagulation therapy after a second episode of venous thromboembolism
57. The rationale for long-term prophylaxis of venous thromboembolism
58. Prevention of venous thromboembolism
59. Use of antithrombotic agents during pregnancy
60. Oral anticoagulant therapy: Efficacy, safety and the low-dose controversy
61. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study
62. Antithrombotic therapy in atrial fibrillation
63. Failure to prescribe warfarin to patients with nonrheumatic atrial fibrillation
64. Antithrombotic therapy in valvular heart disease
65. Antithrombotic therapy in patients with mechanical and biologic prosthetic heart valves
66. Antithrombotic therapy in patients undergoing percutaneous coronary intervention
67. Antithrombotic Agents
68. Intravenous thrombolysis in acute myocardial infarction
69. Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase. Correlation with concomitant heparin, coronary artery patency, and recurrent ischemia
70. Hirudin in acute myocardial infarction. Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial